An Effective Combination Therapy for the Treatment of Pediatric Monomorphic Post-transplant Lymphoproliferative Disorder With Plasmacytic Differentiation.
J Pediatr Hematol Oncol
; 45(5): e624-e627, 2023 07 01.
Article
em En
| MEDLINE
| ID: mdl-36719134
ABSTRACT
Post-transplant lymphoproliferative disorder (PTLD) is a complication of immunosuppressive therapy following solid organ or hematopoietic cell transplantation. Initial treatment typically includes a reduction of immunosuppression with or without rituximab. However, the optimal therapy for PTLD with plasmacytic differentiation is unclear. We present 3 cases of pediatric patients with plasmacytic PTLD. Two patients received a standard rituximab-based approach and relapsed, prompting additional chemotherapy. The third patient was treated with a novel regimen of bortezomib, dexamethasone, and daratumumab. This regimen was safe, well-tolerated, and resulted in a 2-year remission. Larger studies are needed to further explore this regimen.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Vírus Epstein-Barr
/
Linfoma
/
Transtornos Linfoproliferativos
Tipo de estudo:
Etiology_studies
Limite:
Child
/
Humans
Idioma:
En
Revista:
J Pediatr Hematol Oncol
Ano de publicação:
2023
Tipo de documento:
Article